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Abstract
The development of antigen arrays has provided researchers with great tools to identify reactivities against self or foreign
antigens from body fluids. Yet, these approaches mostly do not address antibody isotypes and their effector functions even
though these are key points for a more detailed understanding of disease processes. Here, we present a bead array-based
assay for a multiplexed determination of antigen-specific antibody levels in parallel with their properties for complement
activation. We measured the deposition of C3 fragments from serum samples to reflect the degree of complement
activation via all three complement activation pathways. We utilized the assay on a bead array containing native and
citrullinated peptide antigens to investigate the levels of IgG, IgM and IgA autoantibodies along with their complement
activating properties in serum samples of 41 rheumatoid arthritis patients and 40 controls. Our analysis revealed
significantly higher IgG reactivity against the citrullinated fibrinogen b and filaggrin peptides as well as an IgA reactivity that
was exclusive for citrullinated fibrinogen b peptide and C3 deposition in rheumatoid arthritis patients. In addition, we
characterized the humoral immune response against the viral EBNA-1 antigen to demonstrate the applicability of this assay
beyond autoimmune conditions. We observed that particular buffer compositions were demanded for separate
measurement of antibody reactivity and complement activation, as detection of antigen-antibody complexes appeared
to be masked due to C3 deposition. We also found that rheumatoid factors of IgM isotype altered C3 deposition and
introduced false-positive reactivities against EBNA-1 antigen. In conclusion, the presented bead-based assay setup can be
utilized to profile antibody reactivities and immune-complex induced complement activation in a high-throughput manner
and could facilitate the understanding and diagnosis of several diseases where complement activation plays role in the
pathomechanism.
Citation: Ayoglu B, Szarka E, Huber K, Orosz A, Babos F, et al. (2014) Bead Arrays for Antibody and Complement Profiling Reveal Joint Contribution of Antibody
Isotypes to C3 Deposition. PLoS ONE 9(5): e96403. doi:10.1371/journal.pone.0096403
Editor: Robert B. Sim, Oxford University, United Kingdom
Received January 22, 2014; Accepted April 7, 2014; Published May 5, 2014
Copyright:  2014 Ayoglu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Hungarian Academy of Sciences, the Hungarian Scientific Research Fund (OTKA-PD 104779 and OTKA-NK 104846),
ProNova VINN Excellence Centre for Protein Technology (VINNOVA, Swedish Governmental Agency for Innovation Systems), the J nos Bolyai Research
Scholarship of the Hungarian Academy of Sciences, the Knut and Alice Wallenberg Foundation and SciLifeLab Stockholm. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: J.P. is a paid employee of Diagnosticum Ltd. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and
materials.
* E-mail: pkrisz5@gmail.com (KP); peter.nilsson@scilifelab.se (PN)
. These authors contributed equally to this work.
Introduction
Antigen array-based methods allow screening for hundreds or
thousands of potential targets of antibody reactivities and they are
being increasingly utilized to identify novel antibody reactivities in
the context of various pathological conditions such as autoimmune
diseases [1–3]. The focus of such approaches is mostly limited only
to determine the targets of antibodies, usually of IgG isotype. Yet,
the information on targets of autoantibodies or antibodies towards
infectious agents can be further enriched by screening for other
antibody isotypes and by studying their effector functions.
Antigen-antibody immune complexes can induce various
effector functions including activation of the complement system,
yet the degree of antibody-induced complement activation is
influenced by various factors such as antibody isotype composition,
antibody affinity or glycosylation state [4]. Investigating the
effector functions of antigen-antibody complexes can therefore
potentially add another valuable dimension for categorizing
antigens or classifying clinical samples in any given autoimmune
or infectious disease.
The complement system is one of the first protection lines
against pathogens. More than 30 proteins form an orchestrated
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enzyme cascade, which can be activated by classical, lectin or
alternative pathways of the complement system. All these three
pathways converge at the point of cleavage of the protein C3, the
third complement component, followed by activation of the
common terminal pathways [5]. Various molecular structures are
able to initiate the activation of the complement system, e.g.
immune complexes (classical pathway); certain carbohydrates
(lectin pathway); or several microbes or aggregates of immuno-
globulins (alternative pathway) [6]. The resulting complement
cleavage products induce multiple immunological effects like
opsonization of the antigen, induction of inflammation or lysis of
certain pathogens; some of these effects are important not only for
protection against invading microbes but also play a role in
autoimmune diseases.
Rheumatoid arthritis (RA) is a systemic, inflammatory, auto-
immune disease that affects 0.5–1% of the world population [7].
RA is characterized by formation of rheumatoid pannus in
synovial membranes, which erode adjacent cartilage and bone,
subsequently leading to joint destruction [8,9]. Rheumatoid
factors (RF) – antibodies specific to the Fc part of IgG – can be
detected in up to 70–80% of RA patients [10], but the specificity
of RFs is not adequate as positive results occur in other
autoimmune and infectious diseases and in up to 15% of healthy
individuals, too [9,11]. Therefore, RF performs poorly as a
screening test and should not be ordered in patients with minimal
or no symptoms. Autoantibodies against citrullinated forms of
peptides derived from various proteins are being suggested as
promising disease markers for RA [12]. Citrullinated filaggrin was
the first recognized protein, which proved to be a good candidate
for detection of autoantibodies against anti-citrullinated peptides
(ACPAs) [13]. But filaggrin is expressed in epithelial and not in
RA-affected articular tissue, so citrullinated filaggrin is not the in
vivo target but rather represents an in vitro cross-reactive antigen of
ACPAs [14]. Masson-Bessie`re et al. showed that the main in vivo
targets of citrullinated filaggrin-specific antibodies are deiminated
forms of fibrinogen a and b chains, which are present in
rheumatoid synovial membranes [8]. Other citrullinated protein
targets in the joints like vimentin, collagen type II and a-enolase
have also been previously investigated and some more are waiting
for further characterization [12]. ACPA and RF define overlap-
ping populations of RA patients. Joint destruction, comorbidities
such as cardiovascular disease and other extra-articular manifes-
tations are all prominent in the subset of patients positive for RF
and ACPA [15].
The target of ACPA might be not only an autoantigen but also a
viral antigen such as the citrullinated form of Epstein-Barr virus
encoded nuclear antigen (EBNA-1), suggesting a possible role of
Epstein-Barr virus (EBV) infection in the induction of disease-
specific antibodies in RA [16]. EBV is a human c-herpesvirus that
infects more than 90% of the world population. EBV persists
lifelong in the human host after the primary infection and is well
controlled by the host’s immune system, but it can cause a number
of malignancies of lymphoid and epithelial origin in immunosup-
pressed individuals. EBNA-1 is expressed in all EBV infected cells
and is the only viral protein regularly detected in all malignancies
associated with EBV [17–19]. Antibodies against citrullinated
peptides derived from EBNA-1 in contrast to the native form can
differentiate between RA from non-diseased samples [16].
Assay setups based on suspension bead arrays currently offer a
great sample throughput compared to planar array-based assay,
allowing a highly multiplex analysis of up to 384 analytes in up to
384 samples per assay run [20]. Despite the presence of studies
utilizing planar antigen arrays, there are no established protocols
available to implement suspension bead-arrays for studying
antigen-specific antibody reactivity and complement activation
induced C3 deposition in a single assay. Here we describe
development of an antigen bead-array based method for parallel
detection of antibody isotypes and measurement of their comple-
ment activation properties. Our aim was to determine the optimal
conditions and establish a workflow for parallel analysis of
antibody reactivity and immune-complex induced complement
activation on a suspension bead array platform. We demonstrated
the utility of our method in the context of RA by screening serum
samples for reactivity against citrullinated and non-citrullinated
forms of various RA-related peptides. Furthermore, we tested the




Serum samples were collected after written consent with ethical
permission of the Scientific Research Ethics Committee of the
Medical Scientific Board of Ministry of Human Resources (ETT
TUKEB 5257-0/2010-1018EKU 376/PI/010).
Serum samples
Serum samples were collected from 41 RA patients with
established disease and from 40 healthy volunteers. The diagnosis
of the disease was established on the basis of the revised ACR/
EULAR classification criteria [21]. Sample donor information for
RA patients and non-diseased controls is summarized in Table 1.
Serum samples were aliquoted within less than 2h after blood
collection and were stored at –70uC without being exposed to any
freeze-thaw cycle to preserve the complement activating property.
Peptide synthesis
The N-terminally biotinylated fibrinogen b chain (UniProt:
P02675) derived peptides (Biotinyl-SGSG-60RPAPPPISGG-
GYRAR74 or Biotinyl-SGSG-60XPAPPPISGGGYXAX74 where
X stands for citrulline) [14] were purchased from Mimotopes Ltd.
(Australia). The C-terminally biotinylated filaggrin (UniProt:
P20930) related peptides (454TRGRS458-K-LCbiotin-Ttds or
454TXGRS458-K-LCbiotin-Ttds) were synthesized manually by
solid phase peptide synthesis according to Fmoc/tBu strategy using
biotinyl-6-aminohexanoic acid (LCbiotin) and 4,7,10-trioxa-1,13-
tridecanediamino succinic acid linker (Ttds) and biotin [22,23].
Lysine was added to the C-terminus of the peptide for conjugation
of the biotin derivatives to its e-amino group of the side chain. The
crude products were purified by HPLC. The amino acid sequence
of the peptides was confirmed by ESI mass spectrometry.
Proteins and secondary antibodies
Properdin (Calbiochem); human IgG, IgM and IgA (Sigma);
EBNA-1 protein (Tebu-Bio) and neutravidin (Thermo Scientific)
were coupled to beads and utilized to determine the optimal assay
conditions for measurement of complement activation. For
detecting the various antibody isotypes, goat anti-human IgM (m
chain specific) F(ab’)2 –Cy3, goat anti-human IgG (c chain
specific) F(ab’)2 –PE or goat anti-human IgA (a chain specific)
F(ab’)2 –DyL549 (Jackson ImmunoResearch Laboratories) anti-
bodies were used. Goat anti-human complement C3 specific
F(ab’)2 antibody (MyBioSource) was labeled with R-Phycoerythrin
(Lightning-Link-R-Phycoerythrin Conjugation Kit, Innova Biosci-
ences) according to manufacturer’s protocol and was used to detect
complement activation driven C3 deposition on beads.
On-Bead Complement Activation
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Generation of suspension bead arrays
Proteins were coupled to carboxylated magnetic beads (Mag-
Plex-C, Luminex Corp.) based on a previously published antigen
coupling protocol [2] with minor changes. In brief, 106 beads per
bead identity were distributed across 96-well plates (Greiner
BioOne), washed and re-suspended in phosphate buffer (0.1 M
NaH2PO4, pH 6.2) using a plate magnet and a plate washer
(EL406, Biotek). The carboxyl groups on the surface of the beads
were activated by 0.5 mg of 1-ethyl-3(3-dimethylamino-propyl)
carbodiimide (Pierce) and 0.5 mg of N-hydroxysuccinimide
(Pierce) in 100 ml phosphate buffer. After 20min incubation on a
shaker (Grant Bio), beads were washed in MES buffer (0.05 M 2-
(N-morpholino)ethanesulfonic acid, pH 5.0). For coupling of the
following proteins to beads, 2-fold serial dilutions of the proteins
with indicated starting concentrations were prepared in MES
buffer: human IgG, IgM, IgA and properdin at 160 mg/ml;
recombinant EBNA-1 protein at 80 mg/ml. Beads coupled in
protein-free MES buffer were used as negative control. The
coupling reaction was allowed to take place for 2h at RT, the
beads were then washed 3x in PBS-T (0.05% Tween20 in PBS),
re-suspended in 100 ml storage buffer (1% BSA, 0.05% Tween20,
ProClin300 in PBS) and stored in plates at 4uC overnight. For
efficient coupling of the peptides to the beads, the bead surface was
first modified by covalent coupling of neutravidine (250 mg/ml) as
described above. Then, 100 ml of each biotinylated peptide
solution at 50 mM concentration was added to neutravidin-coated
beads. Following an overnight incubation at 4uC, beads were
washed 3x in PBS-T and re-suspended in 100 ml storage buffer.
The final antigen suspension bead array was prepared by
combining equal volumes of each bead identity and the mixture
was re-suspended in storage buffer. After adjustment of the final
volume to enable the transfer of 5 ml of bead solution per well, the
beads were sonicated (Branson Ultrasonic Corp) and stored at 4uC
until further use.
Assays on suspension bead arrays
Two types of assay buffers were utilized for the analysis of serum
samples. An assay buffer supplemented with Ca2+ and Mg2+
(2.5 mM Ca2+, 0.7 mM Mg2+, 5% BSA, ProClin300 in PBS) was
used for measurement of deposited C3 fragments, whereas an
assay buffer supplemented with EDTA (25 mM EDTA, 5% BSA,
ProClin300 in PBS) was used for detection of various antibody
isotypes. Serum samples were diluted 1:10 (v/v) in assay buffer
supplemented with 100 mg/ml neutravidin and incubated for 45
min on ice for pre-adsorption against neutravidin-specific
antibodies. Using a liquid handler (CyBi-SELMA, CyBio), 50 ml
of 1:10 diluted serum samples were transferred to 384 well plates
containing 5 ml bead array per well. Following incubation at 37uC
on a shaker (Grant Bio) for 1h, beads were washed 6x with 60 ml
PBS-T on a plate washer (EL406, Biotek) and re-suspended in
50 ml of each secondary antibody solution. Anti-human C3–PE
was used for detection of complement activation, whereas anti-
human IgM–Cy3, anti-human IgG–PE or anti-human IgA–
DyL549 antibodies were used for detection of bound antibody
isotypes (Figure 1). All secondary antibodies were diluted 1:500 in
a buffer consisting of 5% BSA, 0.05% Tween20 in PBS. After
incubation with the secondary antibodies for 30 min, the beads
were washed 3x with 60 ml PBS-T and re-suspended in 60 ml PBS-
T for measurement by a FlexMap3D instrument (Luminex Corp.).
At least 50 events per bead identity were counted and binding
events were displayed as median fluorescence intensity (MFI)
values.
Data Analysis
Data analysis and visualizations were performed using R [24]
and various R packages or Prism 4 (GraphPad Software Inc.).
Non-parametric Spearman’s correlation and Mann-Whitney test
were used, values were considered statistically significant if p-value
, 0.05.
Results
Effect of serum sample dilution rate on complement
activation
Complement activation is an enzyme cascade that requires
relatively higher serum concentrations than usually applied for
antibody detection methods. For identifying the optimal serum
dilution rate, human IgG, IgA or properdin were coupled on
beads with the aim of initiating the activation of classical, lectin &
alternative or only alternative pathways, respectively. Beads were
incubated with serially diluted normal human serum and the level
of complement activation was determined by detection of
deposited C3 fragments using an anti-human C3–PE antibody.
Complement activation on beads coupled to classical pathway
activator human IgG decreased with the increased serum dilution
rate, yet a low level of C3 was detected in 1:160 diluted serum
(Figure 2B). C3 detection for the beads coupled to human IgA,
which is the lectin & alternative pathway activator, diminished
when serum was diluted 1:20 or more (Figure 2C). Complement
activation on beads coupled to properdin, which stabilizes the C3
convertase enzyme of the alternative pathway and induces an
extreme activation of the alternative pathway, could be detected
even in serum diluted 1:80 (Figure 2D). Very low MFI values for
C3 detection on beads that were incubated in complement
blocking EDTA supplemented buffer indicated that only the
complement activation and not the passive binding of C3
molecules was measured by this method (Figure 2B, 2C, 2D).
Serum dilutions of 1:5 or less resulted in remarkably elevated
background as revealed by the signal intensities for the ‘‘empty’’
beads, which were not coupled to any protein or peptide
Table 1. Demographics of the serum sample donors.
Atribute RA Group Control Group
Male/Female 10/31 13/27
Age (year) 56 (21–84)a 29 (19–65)
CCP2 Test +/2 38/3
DAS index 4.2 (0.6–8.2)
Disease duration (year) 4.5 (0–32)
aMedian and ranges in brackets are shown, where applicable. DAS - disease activity score.
doi:10.1371/journal.pone.0096403.t001
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(Figure 2A). Therefore, serum dilution rates of less than 1:10 were
not suitable due to high background. On the other hand, the
higher the serum dilution rate, the lower the C3 fragment
deposition was on complement activator-coupled beads, highlight-
ing the trade-off between low background and high MFI values for
C3 detection. Serum diluted 1:10 in the Ca2+- Mg2+ - buffer
resulted in high C3 signal intensities on activator-coupled beads
and yet gave low background on empty beads. Thus, a serum
dilution rate of 1:10 was selected for use in further experiments.
Pronounced complement activation masks detectability
of antibodies
Antibody-antigen immune complexes or directly bead-bound
human antibodies can activate the complement system. Comple-
ment activation results in the deposition of complement fragments
on bead surface and this phenomenon can potentially mask the
detection of bead-bound antibodies. In order to evaluate the
masking effect of complement components on antibody detection,
human IgG or IgM coupled beads were incubated with 1:10
diluted normal human serum under assay conditions promoting
(Ca2+- Mg2+ - buffer) or blocking (EDTA - buffer) complement
activation. Directly bead-bound antibodies were detected by anti-
human IgG – PE and anti-human IgM - Cy3 secondary
antibodies. As Figure 3A and 3B show, substantial complement
deposition entirely diminished the signal intensities for the anti-
human IgG antibody and decreased the signal intensities for the
anti-human IgM antibody. A remarkable loss of signal intensity for
the anti-human IgG antibody was also observed when the viral
antigen EBNA-1 coupled beads were incubated with a seropositive
serum sample (Figure 3C). Furthermore, the masking effect of
complement activation diminished detectability of IgG-specific
IgM rheumatoid factors as well (Figure 3D). Based on these
results, EDTA containing assay buffer was used for detection of
bead bound serum antibodies.
Detection of various rheumatoid factors and their
complement activating properties
Sera of the majority of rheumatoid arthritis patients contain
rheumatoid factors, namely autoantibodies against immunoglob-
ulins [9]. Here, human IgG coupled beads were incubated with
serum samples of RA patients and controls diluted 1:10 in EDTA-
containing assay buffer and the bound human antibodies were
detected by anti-human IgG, anti-human IgM or anti-human IgA
secondary antibodies (Figure 4). Anti-human IgG antibody
expectedly recognized the human IgG molecules coupled on
beads; thus there was no significant difference between RA
patients and controls. On the other hand, RA serum samples
revealed significantly higher MFI values than control samples for
the anti-human IgM and anti-human IgA antibodies, demonstrat-
ing the presence of IgG-specific IgM and IgA rheumatoid factors
in RA patient sera (Figure 4A, Figure S1). The level of
rheumatoid factors of IgM isotype in some serum samples reached
3000 AU, which can be considered as a high value, since the
maximum anti-IgM signal intensities for beads coupled with
highest concentration of IgM revealed 7000 AU. The level of
rheumatoid factors of IgA isotype was relatively low even in RA
patients, since it reached only 250 AU where the maximum anti-
IgA signal intensity for beads coupled with highest concentration
of IgA revealed 6000 AU.
Levels of IgG-specific IgM rheumatoid factors were measured
also by ELISA, which revealed a strong positive correlation
(r = 0.927) between the MFI values obtained on the bead array
platform and the OD values in ELISA (Figure S2A). In parallel,
human IgG coupled beads were also incubated with serum
samples diluted 1:10 in Ca2+ and Mg2+-containing buffer,
providing assay conditions promoting activation of the comple-
ment system and the level of C3 deposition on beads was
measured by the anti-human C3 antibody. Complement activa-
tion on human IgG coupled beads was significantly higher in sera
of RA patients compared to controls (Figure 4A). As Figure 4B
and 4C show, there was a very strong positive correlation
(r = 0.908) between the MFI values for anti-C3 and anti-IgM
antibodies. The correlations between MFI values for anti-IgA and
anti-IgM antibodies (r = 0.74) and anti-IgA and anti-C3 (r = 0.67)
antibodies were comparable.
Complement activating properties of autoantibodies
against citrullinated peptides
Biotinylated citrulline or arginine-containing peptide pairs
derived from filaggrin [36] and fibrinogen b [14] were coupled
at their C- or N-terminal to neutravidin-coated beads through
non-covalent but extremely strong and specific interaction,
respectively. Serum samples needed first to be pre-adsorbed
against neutravidin-specific antibodies before applying on bead
arrays, since a number of serum samples were found to contain
neutravidin-specific IgG and/or IgM antibodies, which would
Figure 1. Schematic representation of assay workflow. A) Serum
samples are diluted 1:10, either in a Ca2+-Mg2+ containing assay buffer
for detection of complement activation, or in an EDTA containing assay
buffer for antibody detection. B) The samples are pre-adsorbed against
neutravidin-specific antibodies. C) A mixture of beads coupled to
various antigens is distributed into a 384-well plate and the pre-
adsorbed samples are added to the bead array. D) Complement
activation driven C3 deposition and different antibody isotypes are
detected in parallel with fluorescently labeled secondary antibodies
dispensed into individual wells of each quadrant of the 384-well plate.
doi:10.1371/journal.pone.0096403.g001
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cause false positive signals (Figure S3A). Thus, both the Ca2+-
Mg2+ or EDTA-containing assay buffers were supplemented with
100 mg/ml neutravidin and the serum samples were diluted 1:10
in these buffers depending on whether C3 deposition or
autoantibody level was measured.
As Figure 5A shows, in sera of RA patients there were only
minimal amount of autoantibodies of IgG, IgA or IgM isotypes
against the arginine-containing form of fibrinogen b chain peptide
(60RPAPPPISGGGYRAR74) in sharp contrast to its citrullinated
form (60XPAPPPISGGGYXAX74). The autoantibodies against
the citrullinated form of fibrinogen b peptide also induced an
increased complement activation in the RA patient group. The
results were different regarding the filaggrin-derived peptides:
complement activating autoantibodies of IgM isotype against the
arginine-containing form of filaggrin (454TRGRS458) were detect-
ed in sera of both RA patients and controls. On the other hand,
citrullinated filaggrin peptide (454TXGRS458) specific IgG anti-
bodies were detected only in sera of RA patients and not of
controls. Peptide-specific IgG autoantibody levels in RA patient
sera were also confirmed by ELISA, where significant correlations
were revealed between bead array and ELISA measurements for
the citrullinated forms of peptides for fibrinogen b and filaggrin
(Figure S2B).
Figure 2. Dependence of complement activation on serum dilution rate. For measuring the background, classical, lectin & alternative and
only alternative pathway activation, a serially diluted serum sample (1:1–1:160) was applied to empty, human IgG, human IgA and properdin-coupled
beads, respectively. The assay buffer for serum dilution contained either Ca2+-Mg2+, which promotes complement activation, or EDTA, which blocks
complement activation. Complement activation-driven C3 fragment deposition on beads was detected by PE-conjugated anti-human C3 antibody.
Plots display for each serum dilution the respective median fluorescence intensity (MFI) value against varying concentrations of human IgG, human
IgA and properdin coupled on beads. AU - arbitrary units
doi:10.1371/journal.pone.0096403.g002
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Antibodies against the viral antigen EBNA-1 and their
complement activating properties
EBNA-1-specific IgG, IgM, IgA levels and their complement
activating properties were measured in serum samples of RA
patients and controls. Only the MFI values for the anti-IgM
antibody on EBNA-1 coupled beads were significantly higher in
sera of RA patients compared to controls (Figure 6A). There was
also a significantly strong (r = 0.714) positive correlation between
the levels of IgG-specific IgM rheumatoid factors and the anti-IgM
signal intensities for EBNA-1 coupled beads (Figure S4.) Since
most of the serum samples contain EBNA-1 specific IgG, the
discriminating property of IgM signal intensities for EBNA-1 was
supposedly derived from the rheumatoid factors that would bind
to the EBNA-1 specific IgG antibody. Accordingly, there was a
very high (r = 0.898) correlation between EBNA-1-specific C3 and
IgG levels especially in control serum samples, which are not
affected by the interference of rheumatoid factors (Figure 6B).
The correlation between EBNA-1-specific IgA and C3 deposition
was lower (p = 0.539) in control serum and non-significant in RA
samples.
Discussion
We herein describe the development and application of a
suspension-bead array based workflow for multiplex and parallel
measurement of antigen-specific antibodies and complement
activation in sera. To our current knowledge, this is the first
study demonstrating the use of multiplex bead arrays for parallel
measurement of antibody reactivity and complement activation
towards various peptides and viral proteins in clinical samples
within the same assay.
The complement system is an important part of the immune
system and assessing the degree of complement activation can
reveal important information about various pathophysiological
processes. Human antibodies of different isotypes in complex with
an antigen can induce complement activation to different extents.
In general, the property of human antibody isotypes regarding
activation of the classical pathway is as follows: IgM, IgG3.
IgG1..IgG2, while IgG4 and IgE do not activate the
complement system and IgA activates only the alternative and
lectin pathways [25]. Yet, different antibody clones of same isotype
can initiate complement activation with very different efficacy
[26], thus the direct measurement of antigen-specific complement
Figure 3. Complement activation masks detectability of antibodies. Human IgG (A,D), human IgM (B) and EBNA-1 (C) coupled beads were
incubated in 1:10 diluted serum. Ca2+- Mg2+ (-N-) or EDTA (-*-) supplemented assay buffer was used for serum dilution. Anti-human C3-PE (black lines
and axes), anti-human IgG-PE (gray lines and axes) or anti-human IgM-PE (gray lines and axes) secondary antibodies were used to measure the
complement activation, IgG or IgM levels, respectively.
doi:10.1371/journal.pone.0096403.g003
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Figure 4. Complement activation by rheumatoid factors. Following incubation of human-IgG coupled beads in sera of RA patients or non-
diseased controls, bound IgG-specific rheumatoid factors and deposited C3 fragments were detected. A) Median fluorescence intensities (MFI) for
anti-IgG, anti-IgM, anti-IgA and anti-C3 secondary antibodies are plotted separately for the RA patients and controls. Statistical differences between
these two groups were calculated by Mann-Whitney non-parametric test. B) Anti-IgA, anti-IgM and anti-C3 MFI values for the human-IgG coupled
bead within RA patient group (D) and controls (&) are plotted in a 3D graph for visualization of their correlation to each other. Anti-IgG MFI values
are excluded from this plot since they not reveal a significant difference between the two groups. C) The table shows the Spearman’s Rho correlation
coefficients between anti-C3, anti-IgG, anti-IgM and anti-IgA MFI values in the entire sample cohort, where only statistically significant (p-value ,
0.05) correlation coefficients are shown and non-significant correlations are indicated by (n.s.).
doi:10.1371/journal.pone.0096403.g004
On-Bead Complement Activation
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Figure 5. Detection of the level and the complement activating properties of autoantibodies against citrullinated peptides. The
arginine or citrulline-containing form of fibrinogen b chain peptide (SGSG60RPAPPPISGGGYRAR74 vs. SGSG60XPAPPPISGGGYXAX74) (A) and filaggrin
peptides (454TRGRS458K vs. 454TXGRS458K) (B) were coupled on beads and incubated with serum samples to detect peptide-specific IgG, IgM, IgA
autoantibody levels and their complement activating properties. Median fluorescent intensity (MFI) values for arginine or citrulline-containing forms
of the peptides in RA patient group (red lines) or the control group (blue lines) are shown in the upper panel. Significance level of differences
between controls and RA patients were calculated only for the citrullinated peptides by Mann-Whitney test and the p-values are indicated in the
upper panel as follow: * p-value,0.05; ** p-value,0.01, ***p-value,0.001. Spearman’s Rho correlation coefficients calculated between anti-C3, anti-
IgG, anti-IgM and anti-IgA MFI values are shown for citrullined (middle panels) or native (lower panels) form of the peptides, where non-significant
correlations are indicated by (n.s.).
doi:10.1371/journal.pone.0096403.g005
On-Bead Complement Activation
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activation has many advantages. The clinical practice currently
mainly focuses on measurement of overall complement activation
and determines CH50 value or the level of C3 and C4 in the
serum. ELISA tests allowing a separate analysis of the three
complement activation pathways are also available [27,28].
However, when the assessment of antigen-specific complement
activation is the goal, especially with the need to evaluate several
candidate antigens in parallel, highly-multiplex systems such as
planar [29] or suspension bead arrays offer a great advantage.
Wahrmann et al. previously showed a flow cytometry-based
bead system to measure HLA alloantigen induced complement
activation. They suggest detection of deposited C1q or C4 split
products as an indication of complement activation and their data
argues against the use of C3 fragment measurement, since it
resulted in an alloantibody independent high background [30].
The authors applied undiluted serum that resulted in a very high
background in our assay as well, but as Figure 2 shows, if the bead
array was incubated with a 1:10 diluted serum the background for
the C3 detection disappeared and the antibody-dependent
complement activation was measureable. In other published
studies, C4 deposition was measured using an undiluted external
complement source [31–34]; or bound externally added purified
human C1q was detected after the antigen-coupled beads were
treated with a mixture of heat-inactivated serum sample and C1q
[35]. We measured C3 deposition as this reflects activation of any
of the three pathways, which is particularly favorable since ACPAs
can induce complement activation both through the classical and
alternative pathways [36].
The own complement system of the tested serum sample itself
was not utilized in any of these previous studies. Yet, utilizing the
serum sample’s own complement system can be favorable, since it
reflects more precisely the individual-specific processes in the
investigated serum sample as not only the presence of the
complement activating antibody but also a responsive complement
system is necessary for the complement activation. Avoiding the
use of an external complement source can be especially attractive
when highly multiplexed systems are used. External complement
sources mostly consist of a mixture of normal human sera and the
more ligand are tested the higher the possibility of getting false
positive results due to using this serum mixture. On the other
hand, inappropriate sample preparation, storage and transporta-
tion conditions or disease-related systemic complement consump-
tion can decrease the complement activating capability of patient
samples, which might lead to false negative results when the
sample’s own complement system is used as the complement
source. Yet, in the presented assay setup, the intactness of the
complement system in each sample can be easily inspected by
including properdin-coupled beads in the assay. Properdin induces
an extreme activation of the alternative pathway leading to C3
fragment deposition [37] and is more suitable as an internal
control than the human IgG, as the RF would not alter the
amount of bound C3 fragments. Very low amount of C3
deposition on properdin coupled beads indicates decreased
complement level and necessitates sample exclusion or further
normalization. By demonstrating that the complement system in
the tested serum samples was intact and functioning with similar
efficiency (Figure S5), we have used the own complement system
of the serum samples which required a very strictly controlled
storage of serum sample aliquots at 270uC by avoiding any
repeated freeze-thaw cycles.
Here, an assay buffer containing physiologically equivalent
concentrations of Ca2+ and Mg2+ ions was used for dilution of
serum samples since these ions are essential for the activation of
classical, lectin or alternative pathways, respectively. In addition, a
relatively more concentrated serum condition is needed for
measurement of complement activation than usually applied for
detection of antibodies, where generally 1:100 or even more
diluted serum can be utilized. Harboe et al. reported that hemolytic
activity of the serum is lost at 1:16 dilution for assaying the
alternative pathway and at 1:1024 dilution for assaying the
classical pathway [38]. We have previously shown that 1:5–1:10
serum dilutions give the highest signal-to-noise ratios for comple-
ment measurement on nitrocellulose-coated protein microarray
slides [39]. Trouw et al. also used a serum dilution of 1:10 in their
ELISA based ACPA induced complement activation measure-
ments [36]. Optimization of the serum dilution rate is though
necessary for each assay platform, as the level of complement
activation depends also on the type of the surface coating.. We
observed a very high background on the empty beads when
applying less than 1:5 times diluted serum, which is presumably
the consequence of continuous alternative pathway tick-over that
gives rise to reactive C3 fragments (Figure 2). Yet, serum diluted
1:10 in the presence of physiologically equivalent concentrations of
Ca2+ and Mg2+ ions provided optimal conditions for complement
measurement. But as Figure 3 shows, this condition was not ideal
for a parallel measurement of bound antibodies. Extensive
complement fragment deposition on the site of activation masks
the bound antibodies and prevents their detectability by the
secondary antibodies. This effect was more pronounced regarding
the detection of IgG than IgM (Figure 3). To circumvent this
effect, either higher serum dilutions can be utilized [39] or the
assay buffer can be supplemented with EDTA, which blocks the
complement activation. Here we used the latter approach since
our aim was to measure antibody levels under assay conditions as
identical as possible to the conditions used for measurement of
complement activation.
Here we have demonstrated the utility of multiplex antigen-
specific complement activation measurement on the bead array
platform both in the context of an autoimmune disease
(rheumatoid arthritis) and for detection of a viral antigen
(EBNA-1). There are evidences that complement activation
contributes to the pathological processes of rheumatoid arthritis
[40]. Rheumatoid factors are anti-human IgG Fc-specific autoan-
tibodies of various isotypes (IgM, IgG, IgA, IgE) [41] and some of
these autoantibodies can activate the complement system. There
are discrepancies among the findings of previous studies concern-
ing the prognostic value of rheumatoid factor isotypes [10,42]. We
determined the levels of rheumatoid factors in sera of RA patients
and non-diseased controls using human IgG coupled beads
(Figure 4). The serum samples in the RA patient group revealed
a significantly higher level of rheumatoid factors of IgM and IgA
isotype than the control group, which is in agreement with the
Figure 6. Level of EBNA-1 specific antibodies and their complement activation. EBNA-1 coupled beads were incubated with sera of RA
patients and controls. A) Levels of bound human IgG, IgM and IgA antibodies along with the degree of complement activation are plotted for the two
groups. Mann-Whitney non-parametric statistical test was used to calculate the statistical difference between the two groups. B) Signal intensities for
anti-IgM, anti-IgA and anti-C3 for the controls (upper panel) and RA patients (lower panel) are plotted in a 3D graph. The tables show the Spearman’s
Rho correlation coefficients between anti-C3, anti-IgG, anti-IgM and anti-IgA signal intensities calculated separately for the control and RA patient
groups. Only statistically significant (p-value,0.05) correlation coefficients are shown and non-significant correlations are indicated by (n.s.).
doi:10.1371/journal.pone.0096403.g006
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findings of previous studies [10]. Rheumatoid factors especially of
IgM isotype induced very strong complement activation and C3
fragment deposition. The correlation between the abundance of
rheumatoid factors of IgM isotype and C3 deposition was very
strong (r = 0.908) (Figure 4C) and the classification power of IgM
rheumatoid factors between RA patients and controls was high
(AUC.0.97) (Figure S1). Samples collected from patients with a
disease other than RA were not included in this study, as it would
go beyond the scope of this study. Though in such a case, the
classification power of rheumatoid factors might presumably be
lower as high levels of rheumatoid factors are known to be present
also in other diseases [11].
Measurement of anti-citrullinated peptide antibodies (ACPAs)
in the context of RA shows higher specificity; in this study two
peptide epitopes, one from fibrinogen b chain [14] and another
one from filaggrin [9,22] protein were tested. These peptides
represented the most dominant epitopes and were investigated in
more detail (Figure 5). IgG reactivity against the citrullinated
version of both fibrinogen b and filaggrin peptides were exclusively
observed only in the sera of RA patients and not in controls. IgA
reactivity against the citrullinated fibrinogen b peptide and C3
deposition also significantly discriminated RA patients from the
controls. On the other hand, there were no significant differences
between RA patients and controls regarding the IgM reactivity
against both of the peptides. Especially in case of the filaggrin
peptide, IgM autoantibodies recognizing even the native form of
the peptide were present in sera of both RA patients and controls.
These findings are in agreement with the results of our previous
study, where the same filaggrin peptide pair was utilized in a
planar protein microarray system [43]. As revealed by the strong
correlation between anti-IgM and anti-C3 signal intensities (r.
0.8), the IgM autoantibodies against the filaggrin peptide present
in sera of both sample cohorts could activate the complement
system and did not result in a significant difference between RA
patients and controls regarding the C3 levels.
Pratesi et al. suggested that also citrullinated forms of viral
proteins such as the Epstein-Barr virus nuclear antigen 1 can be
targets of ACPAs [16]. However, we utilized here only the native
form of the EBNA-1 recombinant protein as a representative viral
antigen and not because of any potential relevance to RA. Based
on the fact that the majority of the population worldwide is
seropositive for EBV, antibodies in sera against the immunodo-
minant EBNA-1 protein are widespread [44] and we have
confirmed this in our study as well (Figure 6A). Yet, we observed
that EBNA-1 specific IgM reactivity significantly differed between
RA patients and the controls. To elucidate this observation
further, we investigated the correlation between the IgM reactivity
against EBNA-1 and the level of rheumatoid factors of IgM
isotype, which indeed revealed a strong correlation (Figure S4).
Thus, the difference between RA patients and controls regarding
the IgM reactivity against EBNA-1 is presumably caused as a
pitfall by the presence of rheumatoid factors of IgM isotype in RA
patient sera. Also Henle et al. previously found that rheumatoid
factors can cause false-positive results in tests for EBNA-1 specific
IgM antibodies [45]. The high level of complement-activating
EBNA-1 specific IgG antibodies presumably overrode the
complement activation of rheumatoid factors since the C3 signal
intensities for EBNA-1 was high in sera of both the RA patients
and controls. The interfering effect of rheumatoid factors
regarding the EBNA-1 reactivity dictated to separately investigate
the data derived from the RA patients and controls. In the control
group, where the interfering effect of rheumatoid factors was not
present, there was a very strong correlation (r = 0.898) between
complement activation and IgG level (Figure 6B). IgA reactivity
against EBNA-1 in a portion of the individuals was present in both
sample groups. EBNA-1 protein contains a glycil-alanine (Gly-Ala)
repeat region that was found as a dominant IgA antigen epitope
for instance in patients with nasopharyngeal carcinoma but it was
also shown that non-diseased serum samples might represent IgA
reactivity against it, although with lower prevalence [46].
In conclusion, the findings we present here illustrate that
antigen-specific immunoglobulin reactivity of various isotypes
towards autoantigens or viral antigens and antigen-specific
complement activation can be measured within the same assay
and in a multiplex format using the suspension bead array
platform. Measuring the C3 deposition allowed here to assess the
joint effect of the three different possible complement pathways.
Here we detected auto- and viral antigen-specific antibodies in the
sera of RA patients and non-diseased controls, we investigated
their complement activating properties and we also showed that
rheumatoid factors have an interfering effect on complement
activation measurement potentially causing false positive results.
The suspension bead array-based workflow we developed and
implemented here can be utilized to investigate any other
autoimmune or infectious disease where the presence of comple-
ment activating antibodies has diagnostic value. Therefore, the
presented approach is an important advancement for the analysis
of autoantibody- or virus-associated immune pathologies.
Supporting Information
Figure S1 Classification power of rheumatoid factors
and their complement activating properties. C3 fragment
deposition and binding of IgM, IgG, IgA antibodies were
measured on human-IgG coupled beads incubated with sera of
40 non-diseased controls and 41 RA patients. Receiver operating
characteristic (ROC) curves and area under the curve (AUC)
values are displayed on the figure.
(PDF)
Figure S2 Correlation between the bead array and
ELISA measurements. A) Level of human IgG-specific IgM
was determined in sera of RA patients by ELISA and on the bead
array platform. Here, an ELISA plate was coated overnight with
5 mg/ml of human IgG in 0.05 M carbonate buffer, pH 9.5.
Following washing with PBS-Tween, wells were blocked with
blocking buffer (1% BSA, 0.05% Tween in PBS) at 37uC for 30
min. Wells were incubated in 200x diluted serum sample (diluted
in blocking buffer) at 37uC for 1h. Following washing, bound
human IgM was detected by rabbit anti-human IgM-HRP
conjugate at 37uC for 1h. After TMB substrate development,
OD was measured at 450 nm (reference 620 nm). B) Peptide-
specific IgG levels in sera of RA patients and controls were also
measured both by ELISA and on the bead array platform. For
ELISA measurements, biotinylated peptides (1 mg/ml in PBS)
were bound to neutravidin (5 mg/ml in PBS) pre-coated plates.
Following washing with PBS-Tween, plates were blocked with
blocking buffer (150 mM NaCl, 2% BSA in PBS) at 37uC for 30
min, then serum samples were added (1:100) in dilution buffer
(2 M NaCl, 2% BSA in PBS). After an overnight incubation and
washing the plate, rabbit anti-human IgG-HRP conjugate was
added for 1h. Following TMB substrate development, OD was
measured at 450 nm (reference 620 nm). The values derived from
the ELISA and the bead array platform are plotted and
Spearman’ Rho correlation coefficients are indicated. OD -
optical density; ELISA - enzyme-linked immunosorbent assay.
(PDF)
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Figure S3 Presence of and pre-adsorption against
neutravidin-specific antibodies in sera. A) Protein micro-
array technique was applied to determine the neutravidin-specific
IgG and IgM levels in sera of each of the controls and RA patients.
In short, 0.33 mg/ml neutravidin was printed in triplicates onto
nitrocellulose covered glass slides by BioOdyssey Calligrapher
miniarrayer (Bio-Rad). Following washing steps with PBS, slides
were incubated with 1:20 diluted serum sample (25 mM EDTA,
5% BSA, 0.05% Tween 20 in PBS) at 37uC for 1h. Bound
antibodies were detected by 1:2500 diluted DyLight 488-
conjugated F(ab’)2 fragment of goat anti-human IgM (m chain
specific) and DyLight 649-conjugated F(ab’)2 fragment of goat
anti-human IgG, (c chain specific) (Jackson ImmunoResearch)
antibodies. The neutravidin-specific IgG and IgM fluorescence
intensity (FI) values of each serum sample are plotted. The arrow
indicates the selected serum sample that was used in further
experiments on the bead array platform. B) Neutravidin or
EBNA-1 coupled beads were incubated in 1:10 diluted, untreated
(black) or neutravidin pre-adsorbed (gray) serum. Here, serum was
diluted in Ca2+-Mg2+ - supplemented buffer for C3 detection and
in EDTA-supplemented buffer for IgG and IgM detection.
Neutravidin pre-adsorption diminished neutravidin-specific C3
and IgG levels, while it substantially decreased IgM levels.
Neutravidin pre-adsorption had no effect on EBNA-1-specific
signal intensities. C) Furthermore, neutravidin pre-adsorption had
no effect on overall complement activation: classical pathway
activator human IgG and alternative pathway activator properdin
were coupled on beads at varying concentrations and incubated
with 1:10 diluted, untreated (black square) or neutravidin pre-
adsorbed (gray circle) serum. C3 fragment deposition was detected
by the anti-human C3-PE antibody and the plots display the
resulting MFI values.
(PDF)
Figure S4 Correlation between anti-IgM signal intensi-
ties for the viral antigen EBNA-1 and for human IgG-
coupled beads. Anti-IgM MFI values for EBNA-1-coupled
beads and for human IgG- coupled beads are plotted and
Spearman’s Rho correlation coefficient is indicated.
(PDF)
Figure S5 Distribution of anti-C3 signal intensities for
properdin-coupled beads. Anti-C3 MFI values for all the
tested serum samples on properdin-coupled beads are plotted.
MFI values for all the samples were within 3 standard deviations
(6 3SD) of the median.
(PDF)
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